CoChat

Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Background: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. Methods: One hundred two FDA-approved targeted cancer drugs were compiled and molecular targets defined. Drugs were considered as potentially effective if targeted genes showed (1) an increase in copy number, (2) gain of function with oncogene activation, (3) specific alterations responsive to approved drugs. Additionally, genetic changes that confer drug resistance and/or sensitivity were evaluated. Results: Fifty percentage of patients with GC may be treatable with non-GC but FDA-approved targeted cancer therapies. The major drug identified in our in silico study for GC is copanlisib, a PI3K inhibitor. In the TCGA patient database, our genetically based drug response prediction identified more patients with alterations sensitive to copanlisib compared to the already-GC-approved drug trastuzumab (20%, 78 out of 393 patients, vs. trastuzumab: 13%, 52 of 393 patients), which is mainly due to the high incidence of PIK3CA gain of function mutations within mutation hot spots. Conclusion: Our results demonstrate that various currently FDA-approved drugs might be candidates for targeted therapy of GC. For clinical trials, cancer patients should be selected based on the genomic profile of their tumor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10120-020-01045-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of data processing: shown are the major steps of data analysis based on the computational query of drugs for targeted therapy on the respective patient’s data with gastric cancer (GC). Further analysis took into consideration gene amplification and gain of function as well as known alterations of genes to reach a conclusion on target options for GC. Abbreviations: FDA Food and Drug Administration; TCGA The Cancer Genome Atlas [9]; CNV Copy Number Variants based on GISTIC 2.0 algorithm [20]; MAF Mutation Annotation Format based on MutSig 2CV algorithm [19]; RPPA reverse phase protein array based on Z-score (overexpression z ≥ 2, underexpression z ≤ − 2) [18]; gene fusion data were taken out of the supplementary of the STAD-TCGA publication [22]; STAD stomach adenocarcinoma; CiViC Clinical Interpretation of Variance in Cancer database [14]; MyCancerGenome database [11]; DoCM Database of Curated Mutations database [46]; OncoKB Precision Oncology Base databases (drugs actionable variance, all variance with biological effects [16]); PCT MD Anderson Center for Personalized Cancer Therapy [13]; COSMIC Catalogue of Somatic Mutations in Cancer database on drug resistance [47].
Fig. 1 Flowchart of data processing: shown are the major steps of data analysis based on the computational query of drugs for targeted therapy on the respective patient’s data with gastric cancer (GC). Further analysis took into consideration gene amplification and gain of function as well as known alterations of genes to reach a conclusion on target options for GC. Abbreviations: FDA Food and Drug Administration; TCGA The Cancer Genome Atlas [9]; CNV Copy Number Variants based on GISTIC 2.0 algorithm [20]; MAF Mutation Annotation Format based on MutSig 2CV algorithm [19]; RPPA reverse phase protein array based on Z-score (overexpression z ≥ 2, underexpression z ≤ − 2) [18]; gene fusion data were taken out of the supplementary of the STAD-TCGA publication [22]; STAD stomach adenocarcinoma; CiViC Clinical Interpretation of Variance in Cancer database [14]; MyCancerGenome database [11]; DoCM Database of Curated Mutations database [46]; OncoKB Precision Oncology Base databases (drugs actionable variance, all variance with biological effects [16]); PCT MD Anderson Center for Personalized Cancer Therapy [13]; COSMIC Catalogue of Somatic Mutations in Cancer database on drug resistance [47].CC BY · PubMed Central
Fig. 2 A network of gene amplification observed in the TCGA patients. Lines signify co-amplification in a given patient. The strongest co-amplification pairs were ERBB2 and RARA (30 patients, RARA targeted by alitretinoin, respectively, ERBB2 i.a. by trastuzumab), followed by PIK3CA and SST (17 patients, PIK3CA targeted by copanlisib, respectively, SST by lanreotide)
Fig. 2 A network of gene amplification observed in the TCGA patients. Lines signify co-amplification in a given patient. The strongest co-amplification pairs were ERBB2 and RARA (30 patients, RARA targeted by alitretinoin, respectively, ERBB2 i.a. by trastuzumab), followed by PIK3CA and SST (17 patients, PIK3CA targeted by copanlisib, respectively, SST by lanreotide)CC BY · PubMed Central
Fig. 3 a The bar-chart represents the 393 TCGA patients analyzed that according to our in silico analysis are predicted to respond to approved target therapies (trastuzumab, ramucirumab, pembrolizumab (T + R + P) in blue); predicted to respond to other FDA-approved targeted drugs (red) and patients with no currently identifiable targeted option (green). b In every line, the upper bar corresponds to the patient group without therapeutically options, the lower bars (corresponding green bar in a) to those with therapeutically options (corresponding to red and blue bar in a). Each bar is further stacked according to the description. From top to down, the following categories were included: STAD-TCGA classification, ACGR classification, CNV cluster, methylation cluster, microRNA cluster, gene expression cluster, KRAS mutated, TP53 mutated, RHOA mutated, CDK2NA epigenetically silenced, microsatellite instability, hypermutated, vital status, outcome, cancer staging, grading, Lauren classification, tumor location, race, gender. A χ2 analysis showed a difference between the patient groups with and without predicted options, whereby significant results are marked with a star (*, p < 0.05) (colour figure online)
Fig. 3 a The bar-chart represents the 393 TCGA patients analyzed that according to our in silico analysis are predicted to respond to approved target therapies (trastuzumab, ramucirumab, pembrolizumab (T + R + P) in blue); predicted to respond to other FDA-approved targeted drugs (red) and patients with no currently identifiable targeted option (green). b In every line, the upper bar corresponds to the patient group without therapeutically options, the lower bars (corresponding green bar in a) to those with therapeutically options (corresponding to red and blue bar in a). Each bar is further stacked according to the description. From top to down, the following categories were included: STAD-TCGA classification, ACGR classification, CNV cluster, methylation cluster, microRNA cluster, gene expression cluster, KRAS mutated, TP53 mutated, RHOA mutated, CDK2NA epigenetically silenced, microsatellite instability, hypermutated, vital status, outcome, cancer staging, grading, Lauren classification, tumor location, race, gender. A χ2 analysis showed a difference between the patient groups with and without predicted options, whereby significant results are marked with a star (*, p < 0.05) (colour figure online)CC BY · PubMed Central
Fig. 4 Listed is the number of patients (y-axis) in the gastric cancer TCGA cohort (total 393 patients) with either amplification (red), a gain of function (green) or a combination of mutations (purple) in a given gene (x-axis). Markedly PIK3CA has a high incidence of gain of function mutation (colour figure online)
Fig. 4 Listed is the number of patients (y-axis) in the gastric cancer TCGA cohort (total 393 patients) with either amplification (red), a gain of function (green) or a combination of mutations (purple) in a given gene (x-axis). Markedly PIK3CA has a high incidence of gain of function mutation (colour figure online)CC BY · PubMed Central
Fig. 5 The y-axis lists all FDA-approved cancer drugs. The x-axis shows the number of GC patients with gene amplification (blue), gain of function mutation (red), both previous alterations (purple) and drug resistance (bright blue). Patients were only counted once within a given drug but could have alterations targeted by multiple drugs. The current standard of care drug trastuzumab is marked with a red line. The yellow line demarcates “significant drug response prediction” over trastuzumab as calculated in Table 1 (colour figure online)
Fig. 5 The y-axis lists all FDA-approved cancer drugs. The x-axis shows the number of GC patients with gene amplification (blue), gain of function mutation (red), both previous alterations (purple) and drug resistance (bright blue). Patients were only counted once within a given drug but could have alterations targeted by multiple drugs. The current standard of care drug trastuzumab is marked with a red line. The yellow line demarcates “significant drug response prediction” over trastuzumab as calculated in Table 1 (colour figure online)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 14

Metadata

Authors
Hescheler, D. A., Plum, P. S., Zander, T., Quaas, A., Korenkov, M., Gassa, A., Michel, M., Bruns, C. J., & Alakus, H.
Affiliations
  • University Hospital Cologne (DE)
  • University of Cologne (DE)
Corresponding author
Alakus, Hakan
Venue
Gastric Cancer
Published
2020-02-27
Volume
23
Issue
4
Pages
627-638
ISSN
  • 1436-3291 (ISSN-L)
  • 1436-3305
OpenAlex
W3007137621
Cited by
12
References
41
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 1 · 2020: 1
FWCI
1.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Gastric Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
gastric adenocarcinoma, targeted therapy, drug repurposing, copanlisib, PI3K inhibitors, PIK3CA mutation, oncogene activation, copy number alterations, drug resistance, drug response prediction, trastuzumab, patient selection for clinical trials
MeSH terms
Adenocarcinoma, Antineoplastic Agents, Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Genome, Human, Drug Resistance, Neoplasm, Genomics, Molecular Targeted Therapy, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. https://app.cochat.ai/papers/10.1007/s10120-020-01045-9
The paper
Hescheler, D. A., Plum, P. S., Zander, T., Quaas, A., Korenkov, M., Gassa, A., Michel, M., Bruns, C. J., & Alakus, H. (2020). Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. Gastric Cancer. https://doi.org/10.1007/s10120-020-01045-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.